C4 Therapeutics (CCCC) Expected to Announce Quarterly Earnings on Wednesday

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 7th. Analysts expect C4 Therapeutics to post earnings of ($0.48) per share and revenue of $3.54 million for the quarter.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.11. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. The firm had revenue of $7.20 million for the quarter, compared to the consensus estimate of $3.54 million. On average, analysts expect C4 Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

C4 Therapeutics Trading Up 9.2%

Shares of NASDAQ:CCCC traded up $0.14 on Monday, hitting $1.61. The company had a trading volume of 541,032 shares, compared to its average volume of 1,418,211. C4 Therapeutics has a 1-year low of $1.09 and a 1-year high of $7.66. The stock has a market cap of $113.97 million, a price-to-earnings ratio of -0.94 and a beta of 3.10. The stock has a 50 day moving average price of $1.67 and a 200 day moving average price of $3.22.

Analyst Ratings Changes

Separately, UBS Group raised shares of C4 Therapeutics to a "hold" rating in a research report on Friday, February 14th.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.